What the label reports
The Neurontin label describes reported symptoms after abrupt discontinuation, including anxiety, insomnia, nausea, pain and sweating. It also warns about the risk of seizures when treatment is stopped suddenly.
Read the Neurontin prescribing information, sections 5.6 and 9.3 ↗The April 2025 label also describes reported suicidal behavior or thoughts after discontinuation. These reports do not establish what caused an individual event. This is an update to the information summarized here, not a newly issued 2026 warning. Learn how to read label dates.
Get medical guidance before making changes
Do not stop gabapentin or alter your dose based on litigation advertising. Your prescriber should assess symptoms and advise on treatment. This site does not provide a tapering schedule.
Dependence and addiction are different
A body’s adaptation to medication and symptoms after stopping do not, by themselves, establish an addiction diagnosis. Describe your experience to your clinician rather than relying on a label from an advertisement.
Document what happened
- Record the dose before and after a change, and when the change occurred.
- Keep your prescribing instructions and pharmacy dispensing history.
- Note when symptoms began and what medical care you received.
- Preserve communications about stopping treatment or reducing a dose.
A reported symptom does not automatically support a lawsuit. The medical explanation, warnings provided and applicable legal rules need individual assessment.
